EHSI Technology Deals Could See Lucrative Benefit from New FDA Stem Cell Decision

HOUSTON--(BUSINESS WIRE)-- Emerging Healthcare Solutions, Inc. (Pink Sheets:EHSI): Last week, the US Food and Drug Administration gave their highly-anticipated approval for the first clinical trial using human embryonic stem cells (hESCs), which are the type of cells that can develop into all tissues of the body. Geron Corporation of Menlo Park, California, received the green light from the US FDA to use cells derived from hESCs to treat people with acute spinal cord injuries. Ten people will receive injections into the injury site of hESC-derived oligodendrocyte progenitor cells, which stimulate the growth of new and severed nerves and recoat damaged nerves with myelin. The hope is that the injections will help people recover function lost through injury, as seen in rodent studies in 2005.

Geron first received permission to proceed in January last year, only for the FDA to withdraw it in August following studies showing that some animals developed benign cysts around the injection sites. Further animal studies led to the FDA's change of heart.

EHSI has previously announced locking down an option for a profit participation deal with biotech firm Celulas Genetica. Celulas Genetica works to develop new major medical solutions using adult stem cell research and is working toward playing a leading role in the development of new medical breakthroughs. EHSI is aggressively seeking to secure various cutting-edge stem cell technologies and is attempting to acquire their first stem cell bioreactor.

Stem cell research stocks in the Biotechnology sector that give context to the importance of this exploding industry include ViaCell (NASDAQ: VIAC), a Cambridge, Massachusetts company backed by biotech giant Amgen (NASDAQ: AMGN) and Genzyme (NASDAQ: GENZ). The Biotechnology sector also includes Biogen Idec (NASDAQ: BIIB).

About Emerging Healthcare Solutions, Inc.

Emerging Healthcare Solutions, Inc. is a medical technology company that works to bring new and innovative medical technologies to the market. The Company’s model is to engage a technology prior to its inflection point in order to maximize the profits available to EHSI as that new technology is adopted. Our common stock is traded under the symbol EHSI.

For more information, visit www.emerginghealthcaresolutionsinc.com.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipate" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the company to differ materially from those expressed or implied by such forward-looking statements. In addition, description of anyone's past success, either financial or strategic, is no guarantee of future success. This news release speaks as of the date first set forth above and the company assumes no responsibility to update the information included herein for events occurring after the date hereof.



CONTACT:

Emerging Healthcare Solutions Inc.
Cindy Morrissey, 713-821-1486

KEYWORDS:   United States  North America  Texas

INDUSTRY KEYWORDS:   Stem Cells  Health  Biotechnology  FDA

MEDIA:

Suggested Articles

Xcovery's ALK inhibitor shrank tumors in 75% of lung cancer patients, compared to 67% for Pfizer's Xalkori, the first FDA-approved drug of that class.

The FDA accepted the regulatory filing for Biogen's once-failed Alzheimer's drug, aducanumab, with plans to decide its fate by March 7, 2021.

Alexion named a chief diversity officer, while COVID-19 vaccine player has two new members of its C-suite.